Clincosm LogoSign in Get a demo

HIV-1-infection

Showing 76 - 100 of 230
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

HIV-1-infection Trial in Spain (Dolutegravir/Lamivudine as a single pill, Bictegravir/Emtricitabine/Tenofovir alfenamide as a

Recruiting
  • HIV-1-infection
  • Dolutegravir/Lamivudine as a single pill
  • Bictegravir/Emtricitabine/Tenofovir alfenamide as a single pill.
  • Alcorcón, Madrid, Spain
  • +28 more
Jun 20, 2022

HIV-1-infection Trial in Kenya, Uganda, Zambia (Vaccine, Placebo)

Active, not recruiting
  • HIV-1-infection
  • Vaccine
  • Placebo
  • Kilifi, Kenya
  • +3 more
Jun 21, 2022

HIV-1-infection, Inflammation, AIDS Trial in Worldwide

Not yet recruiting
  • HIV-1-infection
  • +2 more
    • Brussels, Belgium
    • +24 more
    Jun 13, 2022

    HIV-1-infection Trial (TASSO device)

    Not yet recruiting
    • HIV-1-infection
    • TASSO device
    • (no location specified)
    Jun 9, 2022

    HIV-1-infection Trial in Gainesville (Survey, Focus Group, Usability study)

    Active, not recruiting
    • HIV-1-infection
    • Survey
    • +2 more
    • Gainesville, Florida
      University of Florida
    Jun 10, 2022

    HIV-1-infection Trial in Johannesburg (Doravirine/Lamivudine/Tenofovir)

    Recruiting
    • HIV-1-infection
    • Johannesburg, Gauteng, South Africa
    • +2 more
    Jun 6, 2022

    HIV-1-infection Trial in Worldwide (Dolutegravir & Rilpivirine 2 drug fixed dose combined therapy)

    Active, not recruiting
    • HIV-1-infection
    • Dolutegravir & Rilpivirine 2 drug fixed dose combined therapy
    • Antwerp, Belgium
    • +28 more
    May 23, 2022

    HIV-1-infection Trial in Kisumu, Nairobi (Switch to B/F/TAF, Continue current regimen)

    Active, not recruiting
    • HIV-1-infection
    • Switch to B/F/TAF
    • Continue current regimen
    • Kisumu, Kenya
    • +1 more
    May 24, 2022

    HIV-1-infection Trial (10 mg ?9-tetrahydrocannabinol (THC), 600 mg cannabidiol (CBD), Placebo)

    Not yet recruiting
    • HIV-1-infection
    • 10 mg Δ9-tetrahydrocannabinol (THC)
    • +2 more
    • (no location specified)
    May 17, 2022

    HIV-1-infection, Gonorrhea Male, Chlamydia Trial in Lima (EPT)

    Recruiting
    • HIV-1-infection
    • +3 more
    • EPT
    • Lima, Peru
      Asociacion Civil Via Libre
    May 16, 2022

    HIV-1-infection Trial (UB-421 SC)

    Not yet recruiting
    • HIV-1-infection
    • UB-421 SC
    • (no location specified)
    May 12, 2022

    Tuberculosis, HIV-1-infection, Immuno-Deficiency Trial in Worldwide (Intensified TB treatment (initial phase), WHO standard TB

    Recruiting
    • Tuberculosis
    • +2 more
    • Intensified TB treatment (initial phase)
    • WHO standard TB treatment (initial phase)
    • Phnom Penh, Cambodia
    • +5 more
    May 3, 2022

    HIV-1-infection Trial in Liège (Dolutegravir 50 MG)

    Recruiting
    • HIV-1-infection
    • Dolutegravir 50 MG
    • Liège, Belgium
      Liège university hospital
    Apr 27, 2022

    HIV-1-infection Trial in L'Hospitalet De Llobregat (Doravirine, Descovy)

    Completed
    Has Results
    • HIV-1-infection
    • L'Hospitalet De Llobregat, Barcelona, Spain
      Hospital Universitari de Bellvitge
    Apr 27, 2022

    Lamivudine and Dotiravir Sodium Tablets in Treatment-naïve HIV-1

    Not yet recruiting
    • HIV-1-infection
    • Lamivudine and Dotiravir Sodium Tablets
    • (no location specified)
    Apr 10, 2022

    HIV-1-infection Trial in Los Angeles (Elsulfavirine)

    Recruiting
    • HIV-1-infection
    • Los Angeles, California
      Altasciences Clinical Los Angeles, Inc.
    Apr 11, 2022

    Pregnancy, HIV-1-infection Trial (Standard dose Truvada®, Pregnancy-adjusted dose Truvada®)

    Withdrawn
    • Pregnancy
    • HIV-1-infection
    • Standard dose Truvada®
    • Pregnancy-adjusted dose Truvada®
    • (no location specified)
    Mar 28, 2022

    HIV-1-infection Trial in Los Angeles, San Francisco (PENNVAX-GP, INO-6145, INO-9012)

    Completed
    • HIV-1-infection
    • PENNVAX-GP
    • +3 more
    • Los Angeles, California
    • +1 more
    Apr 4, 2022

    HIV-1-infection Trial in Liuzhou, Najing, Tianjin (B/F/TAF, TDF/3TC/EFV)

    Recruiting
    • HIV-1-infection
    • Liuzhou, Guangxi, China
    • +2 more
    Mar 31, 2022

    HIV-1-infection Trial in Worldwide (Saline, Lefitolimod, 3BNC117 and 10-1074)

    Active, not recruiting
    • HIV-1-infection
    • Salt Lake City, Utah
    • +7 more
    Mar 30, 2022

    HIV-1-infection Trial in Kampala (Integrating PrEP delivery)

    Enrolling by invitation
    • HIV-1-infection
    • Integrating PrEP delivery
    • Kampala, Uganda
      Infectious Diseases Institute, Makerere University
    Mar 28, 2022

    HIV-1-infection Trial in Baltimore (Mobile-enhanced Engagement Intervention)

    Active, not recruiting
    • HIV-1-infection
    • Mobile-enhanced Engagement Intervention
    • Baltimore, Maryland
      Center for Adolescent and Young Adult Health at Johns Hopkins Ha
    Mar 29, 2022

    HIV-1-infection Trial in San Francisco, Saint Louis, Camden (EBT-101)

    Recruiting
    • HIV-1-infection
    • EBT-101
    • San Francisco, California
    • +2 more
    Mar 24, 2022

    HPV Positive Oropharyngeal Squamous Cell Carcinoma, HIV-1-infection, HPV Infection Trial in São Paulo, Cuernavaca, San Juan (9

    Recruiting
    • HPV Positive Oropharyngeal Squamous Cell Carcinoma
    • +2 more
    • 9 valent human papillomavirus vaccine (Types 6, 11, 16, 18, 31, 33, 45, 52, 58)
    • Saline Placebo
    • São Paulo, Brazil
    • +2 more
    Mar 25, 2022

    HIV-1-infection Trial in Montréal (abacavir, dolutegravir and lamivudine dispersible tablets, Triumeq Dispersible Tablets 5 mg

    Completed
    • HIV-1-infection
    • abacavir, dolutegravir and lamivudine dispersible tablets
    • Triumeq Dispersible Tablets 5 mg GSK1349572 [Dolutegravir]/ 60 mg Abacavir/ 30 mg Lamivudine
    • Montréal, Quebec, Canada
      Altasciences
    Mar 10, 2022